Skip to main content
Adocia logo

Adocia — Investor Relations & Filings

Ticker · ADOC ISIN · FR0011184241 LEI · 969500ZL79KYH9PTYP78 PA Real estate activities
Open in API
Filings indexed 828 across all filing types
Latest filing 2014-12-29 Report Publication Anno…
Country FR France
Listing PA ADOC

About Adocia

https://www.adocia.com

Adocia is a clinical-stage biotechnology company that specializes in developing innovative treatments for metabolic diseases, with a primary focus on diabetes and obesity. The company's core expertise is the development of novel formulations of approved peptides, proteins, and metabolic hormones, such as insulin, to improve their therapeutic efficacy. Adocia leverages proprietary technology platforms to create a pipeline of specialty products. Its research also extends to novel cell therapy approaches, including an immunoprotective scaffold for cell delivery. The company's business model involves advancing its product candidates to clinical proof-of-concept before licensing them to partners for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Report Publication Announcement Classification · 1% confidence The document is a press release dated December 29, 2014, announcing the company's financial calendar for the upcoming year 2015. It lists dates for the publication of Q4/full-year revenue, 2014 financial statements, Q1/Q3 revenue, mid-year statements, and the Annual Shareholders' Meeting. Since the document's primary purpose is to announce *when* future reports and meetings will occur, rather than being the report itself (like an ER, IR, or 10-K), it fits the definition of a Report Publication Announcement (RPA). The document length (4764 chars) is relatively short, supporting the idea that it is an announcement rather than the full report.
2014-12-29 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and its primary content is announcing the company's financial calendar for the year 2015. It lists dates for the publication of Q4 2014 revenue, full-year 2014 results, Q1 2015 revenue, half-year results, and the date of the Annual General Meeting (AGM). Since the document itself is an announcement *about* future reports and events, rather than the reports themselves (like the 10-K or IR), it fits best under the category for announcements regarding the publication of reports or general regulatory news. Given the specific nature of announcing a schedule of future financial publications, the most appropriate classification is Report Publication Announcement (RPA). It is not the actual Earnings Release (ER) or Interim Report (IR), but the schedule for them. It is too specific for the general Regulatory Filings (RNS) fallback.
2014-12-29 French
Communicated under the obligation to provide permanent information / Other communications
Earnings Release Classification · 1% confidence The document is explicitly titled "Press Release" and is dated December 22, 2014. It announces a significant event: a license agreement on BioChaperone Lispro with Eli Lilly, and subsequently invites shareholders to two conference calls to discuss this agreement and ongoing projects. This structure—a formal announcement of a major business event followed by scheduling calls for discussion—is characteristic of an Earnings Release (ER) or a general corporate update. Since it is a press release announcing key business developments and inviting calls, it fits best under the Earnings Release (ER) category, which covers initial announcements of periodical results or significant corporate news, even if it's not strictly quarterly earnings. It is not a full 10-K, an Audit Report (AR), or a specific regulatory filing like DIRS or DIV. It is an announcement, not a report publication announcement (RPA) which typically just states a report is available. FY 2014
2014-12-22 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and is addressed as a "lettre aux actionnaires" (letter to shareholders). It announces a major licensing deal with Eli Lilly and invites shareholders to two conference calls to discuss the partnership and ongoing projects. This format—a brief announcement summarizing significant corporate news (a major deal) and inviting participation in follow-up discussions (conference calls)—is characteristic of an Earnings Release (ER) or a general corporate update. Since it is a press release announcing significant business developments rather than a full financial report (like 10-K or IR) or a specific regulatory filing, and it focuses on the business impact of the deal, the most appropriate classification is Earnings Release (ER), as these often accompany or precede detailed financial reporting periods, or serve as major operational updates. It is not a Call Transcript (CT) because it is the announcement, not the transcript itself. It is not an Investor Presentation (IP) as it lacks the typical slide structure. It is not a Report Publication Announcement (RPA) because it is providing substantive news (the deal) rather than just announcing the publication of a separate report. Given the context of a major business event announcement via a press release, ER is the best fit among the options provided for a significant, non-periodic operational update.
2014-12-22 French
Communicated under the obligation to provide permanent information / Other communications
M&A Activity Classification · 1% confidence The document is a press release announcing a new strategic partnership and licensing agreement between Eli Lilly and Adocia for the development of a medical product (BioChaperone Lispro). It details the financial terms of the collaboration, including upfront payments and milestone potential. Since this document describes a specific business transaction/merger-like activity (licensing/collaboration) rather than a recurring financial report or regulatory filing, it falls under M&A Activity (TAR).
2014-12-19 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
M&A Activity Classification · 1% confidence The document is titled 'COMMUNIQUE DE PRESSE' (Press Release) and announces a global licensing agreement between Eli Lilly and Adocia regarding the co-development of an ultra-rapid insulin (BioChaperone Lispro). It details financial terms (upfront payment, milestones, royalties) and future development responsibilities. This type of announcement, detailing a significant business transaction, partnership, or financing arrangement, aligns best with the 'Capital/Financing Update' (CAP) category, as it involves substantial financial commitments and potential future revenue streams related to drug development and commercialization rights. While it is a press release, the core subject matter is a major financing/licensing deal, making CAP more specific than the general 'RPA' or 'RNS'. The document length (5799 chars) is substantial enough to be the primary announcement itself, not just a notification of an attachment.
2014-12-19 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.